Stay updated with breaking news from Immunexpress Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marketresearch.biz reports that the Sepsis Diagnostics Market size is expected to be worth around USD 1.8 Bn by 2032 from USD 0.9 Bn in 2022, growing at a CAGR of 7.8% during the forecast period from 2023 to 2032.Overview of the Sepsis Diagnostics MarketThe Sepsis Diagnostics Market focuses on technologies and tests...
Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that SeptiCyte® RAPID has received regulatory clearance by the Australian Therapeutic Goods Administration (TGA). The clearance of the company's flagship medical device by the regulatory body allows for the sale, use and further commercial testing of SeptiCyte RAPID throughout Australia to differentiate infection-positive (sepsis) from infection-negative systemic in
/PRNewswire/ -- According to Coherent Market Insights, Global Sepsis Diagnostics Market size was valued at US$ 841.4 Million in 2023 and is expected to surpass...
/PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today...
/PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostics company focused on rapid diagnosis and improved outcomes for suspected sepsis patients, today...